A harm-reduction look at SR9009, its exercise-mimetic claims, and the poor oral bioavailability that undercuts most real-world use.
At a glance
SR9009, sold as stenabolic, is a REV-ERB agonist often described as an exercise mimetic - a compound proposed to reproduce some metabolic effects of exercise by acting on circadian and metabolic pathways. It is not a SARM and does not touch the androgen receptor.
The single most important practical fact comes first: SR9009 has very poor oral bioavailability. The animal research it is based on used injection, and oral dosing in humans is thought to result in minimal systemic exposure. This means much of the marketing may not translate to real effects when taken as a pill. This is an educational tracking guide, not a recommendation, and not medical advice.
The honest headline is that oral SR9009 is poorly bioavailable, so claims drawn from injected rodent studies may not apply to a human taking it by mouth. There is no long-term human safety data, and as an unregulated research chemical it carries the usual risks of mislabeling and contamination. Anyone using it should treat both its benefits and its risks as largely uncharacterized.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.